AIP Genotype

Most pituitary tumors appear in middle age with no obvious cause. But when one shows up in a teenager or a person in their twenties, grows unusually large, or runs in a family, an inherited gene change is often behind it.

Knowing whether you carry that change matters. Carriers found through screening, before symptoms start, tend to have smaller tumors and better outcomes than those diagnosed only after problems appear.

What This Gene Does

This test looks at the AIP (aryl hydrocarbon receptor-interacting protein) gene. It codes for a small protein made inside cells, and in the pituitary gland this protein acts as a brake on cell growth, a role scientists call a tumor suppressor.

When you inherit a version of the gene that no longer works properly, that brake weakens, and pituitary cells become more likely to overgrow into a tumor. Most disease-causing changes are ones that cut the protein short or stop it from being made, rather than ones that create a harmful new protein. This is a fixed germline result, meaning it comes from the DNA you were born with and does not change over your lifetime.

Acromegaly, Gigantism, and Growth Hormone Tumors

The strongest link is to tumors that overproduce growth hormone (the hormone that drives body growth). These cause gigantism when they start in childhood and acromegaly, a slow coarsening and enlargement of the hands, feet, and face, when they start in adulthood.

In a large international series of people carrying a disease-causing AIP change, growth-hormone-producing tumors made up 78.1% of cases. Compared with acromegaly patients without an AIP change, these tumors were larger, more invasive, and diagnosed roughly two decades earlier. If a pituitary tumor appears at an unusually young age, this gene is one of the first inherited causes worth ruling in or out.

Young-Onset and Large Tumors

The chance of finding an AIP change depends heavily on who is tested. Across unselected people with a seemingly one-off pituitary tumor, the rate is low, but it climbs sharply in the young.

Sources: Daly et al. 2007 (about 15%) and Igreja et al. 2010 (31% in a somatotropinoma-enriched cohort); Cazabat et al. 2012 (443 patients); Tichomirowa et al. 2011 (young patients). More recent summaries put the figure across all such families closer to 10 to 15%.

What this means for you: the value of testing rises steeply if a pituitary tumor was diagnosed before about age 30, was large or invasive, or appears alongside other affected relatives. In those situations an inherited cause is far more likely than in a typical later-life tumor.

Prolactinomas and Other Pituitary Tumors

Although growth-hormone tumors dominate, AIP changes also show up in tumors that overproduce prolactin (the hormone that drives breast milk production), where carriers tend to have invasive tumors at a younger age. Less commonly, the gene is linked to non-functioning adenomas, and rarely to cortisol-producing tumors.

One practical point: an AIP change is enriched in growth-hormone and prolactin tumors and in younger patients, and it is uncommon in the average later-onset adenoma.

Treatment Response

Carrier status can also hint at how a tumor may behave. Growth-hormone tumors with an AIP change tend to respond less well to somatostatin analogs, the standard medications used to shrink them and lower hormone levels, and often need more interventions to control.

In one series of people whose growth-hormone tumors resisted somatostatin treatment and had no family history, about 8% still carried an AIP change or a variant of uncertain meaning. A positive result can therefore reframe why a tumor is proving stubborn and prompt earlier, more aggressive management.

Carrying the Change Does Not Guarantee Disease

This is not an all-or-nothing marker. In families with an AIP change, only about 20 to 30 out of every 100 carriers actually develop a pituitary tumor, and many carriers stay completely healthy. That incomplete relationship is why unaffected carriers are common and why a positive result is best understood as a raised risk, not a diagnosis or a certainty.

The flip side matters too. When relatives who carry the change are screened before any symptoms, previously unrecognized pituitary disease is sometimes found, with roughly a quarter of screened carriers turning out to have some pituitary abnormality. A negative screen today does not close the book, which is why carriers benefit from ongoing monitoring rather than a single check.

Why This Is a One-Time Test

Because your genotype is set from birth, this result never changes and does not need to be repeated. There is no trend to track and no benefit to retesting the same gene by the same method. The only reason to test again is confirmation by a different laboratory technique if the first result is in question.

The lasting value comes from what you do with the result over years, not from redrawing it. If you carry a disease-causing change, the tests that should be tracked are the downstream ones: hormone levels such as IGF-1 (insulin-like growth factor 1, which reflects growth hormone activity) and prolactin, along with periodic pituitary MRI. A reasonable rhythm for carriers is a baseline hormone and imaging check on diagnosis, then repeat clinical and hormonal screening on a schedule set with an endocrinologist, since disease can emerge later even after a normal first look.

What to Do With an Unexpected Result

If you learn you carry a disease-causing AIP change, the next steps are a referral to an endocrinologist, a baseline pituitary MRI, and hormone testing including IGF-1 and prolactin. A genetics professional can help interpret the specific variant and plan cascade testing, meaning offering the test to first-degree relatives such as parents, siblings, and children, since each has a 50% chance of sharing it.

If you already have a pituitary tumor and this test comes back negative but suspicion is high, do not treat it as the end of the workup. Standard sequencing can miss large deletions of the gene, which require a separate dosage method to detect, and other inherited causes such as MEN1 (multiple endocrine neoplasia type 1) may need their own testing. A reported variant of uncertain significance should be reassessed over time, because classifications change: the recurrent change p.Arg304Gln, once treated as harmful, is now considered likely benign.

When Results Can Be Misleading

A genetic result carries its own traps, distinct from anything you ate or did before the draw.

• What the panel can detect: the assay only reads the specific variants it is designed to find. A negative result lowers but does not fully eliminate the chance of a rare change, and large deletions can be missed without a dosage method.
• Uncertain variants: an unexpected change may be reported as a variant of uncertain significance, meaning its effect is unknown. It should not be treated as clearly harmful until further evidence classifies it.
• Ancestry effects: some AIP changes are more common in particular populations, so the meaning of a result depends partly on your background and family history.
• Consumer versus clinical testing: a direct-to-consumer report that mentions this gene may not cover the same variants, or use the same confirmation standards, as a clinical-grade genetic test.